Merchandise of Hims & Hers displayed.
Hims & Hers
Digital pharmacy startup Hims & Hers Well being is introducing entry to compounded GLP-1 weight reduction injections, the corporate introduced Monday.
The corporate, which affords a variety of direct-to-consumer therapies for situations like erectile dysfunction and hair loss, launched a weight reduction program in December. However GLP-1 medicines — the category of medication like Ozempic and Wegovy which have skyrocketed in reputation — weren’t beforehand provided as a part of that program.
Prospects can entry the compounded GLP-1 medicines through a prescription from a licensed healthcare supplier on the Hims & Hers platform. Hims & Hers mentioned it plans to make branded GLP-1 medicines out there to its prospects as soon as constant provide is offered.
The corporate’s oral treatment kits begin at $79 a month, and its compounded GLP-1 injections will begin at $199 a month.
Even earlier than it added compounded GLP-1s to its portfolio, Hims & Hers mentioned in its fourth-quarter earnings report that it expects its weight reduction program to herald greater than $100 million in income by the tip of 2025. The corporate plans to supply up to date steering in its subsequent earnings report.
The GLP-1 market, dominated up to now by pharmaceutical large Novo Nordisk, has confronted provide constraints in latest months because the medicine get expanded approval from well being regulators and elevated well being protection.
GLP-1s work by mimicking a hormone produced within the intestine to tamp down an individual’s urge for food and regulate their blood sugar. When these medicines are in scarcity, sure producers can put together a compounded model of them so long as they meet sure necessities from the FDA.
In a January launch, the U.S. Meals and Drug Administration mentioned sufferers shouldn’t use a compounded GLP-1 drug if an permitted drug like Wegovy is offered to them.
Hims & Hers CEO Andrew Dudum instructed CNBC the corporate is “assured” that prospects will be capable to entry a constant provide of the compounded medicines.
Dudum mentioned Hims & Hers has spent the final yr studying concerning the GLP-1 provide chain and has partnered with one of many largest generic producers within the nation that has FDA oversight.
“We now have a sure diploma of exclusivity with that facility that can assure our customers constant quantity and provide,” he mentioned in an interview.
